Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2012-000967-25-NO
EUCTR2012-000967-25-NO
Active, Not Recruiting
N/A

Concomitant Radiotherapy and Erlotinib in advanced lung cancerThoRaT-studienThoracal Radiotherapy and Tarceva®An open randomized multicenter phase II study - ThoRaT

Not provided0 sitesMay 15, 2012
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionson-small cell lung cancer, - palliative treatmentTherapeutic area: Diseases [C] - Cancer [C04]
DrugsTarceva

Overview

Phase
N/A
Intervention
Not specified
Conditions
on-small cell lung cancer, - palliative treatment
Sponsor
Not provided
Status
Active, Not Recruiting
Last Updated
13 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 15, 2012
End Date
TBD
Last Updated
13 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
Not provided

Eligibility Criteria

Inclusion Criteria

  • •Inclusion crieteria
  • •Age \>18 years
  • •Histological or cytological verified NSCLC
  • •ECOG Performance status 0\-2
  • •Fertile patients must use contraception
  • •Signed informed consent
  • •Ability to understand and fill in QoL questionnaires
  • •Capability to take per os medication
  • •Serum bilirubin \< 2 times upper limit of normal (ULN)
  • •AST and ALT \< 2 times ULN (\< 5 times ULN if liver metastases are present)

Exclusion Criteria

  • •Exclusion criteria
  • •Pregnancy or nursing
  • •Other prior or concurrent malignant disease likely to interfere with study treatment or comparisons
  • •No evidence of other significant laboratory finding or concurrent uncontrolled medical illness, that in the opinion of the investigator, would interfere with study treatment or results comparison or render the patient at high risk for treatment complications
  • •No prior radiotherapy to the same organ / place
  • •No concurrent treatment with other experimental drugs
  • •Known brain metastases in need of radiotherapy

Outcomes

Primary Outcomes

Not specified

Similar Trials

Terminated
Phase 2
Thoracal Radiotherapy and TarcevaCancer
NCT02714530Oslo University Hospital118
Unknown
Phase 2
Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)Non-small Cell Lung Cancer
NCT01091376Zhejiang Cancer Hospital75
Completed
Phase 2
A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell CarcinomaCancer
NCT00369512University of Alabama at Birmingham15
Unknown
Phase 2
Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21Non-small Cell Lung Cancer
NCT01714908Jinming Yu100
Active, Not Recruiting
N/A
PHASE I/II TRIAL OF ERLOTINIB, RADIATIONTHERAPY, AND CISPLATIN IN PATIENTS WITH COMPLETE RESECTED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECKEnsayo Fase I/II de Erlotinib en combinación con radioterapia y cisplatino en pacientes con carcinoma epidermoide de cabeza y cuello localmente avanzado resecado quirúrgicamente
EUCTR2005-001506-29-ESGroup of Clinical Investigation in Radiotherapy Oncology (GICOR)90